Verona Pharma Plc ADR [VRNA] stock is trading at $66.81, up 0.81%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VRNA shares have gain 8.83% over the last week, with a monthly amount glided 4.08%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on January 10, 2025, when ROTH MKM initiated its Buy rating and assigned the stock a price target of $68. Previously, Wells Fargo started tracking the stock with Overweight rating on October 03, 2024, and set its price target to $50. Piper Sandler initiated its recommendation with a Overweight and recommended $31 as its price target on August 26, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on September 13, 2021, and assigned it a price target of $25. In a note dated August 25, 2020, Jefferies initiated an Buy rating and provided a target price of $17 on this stock.
Verona Pharma Plc ADR [VRNA] stock has fluctuated between $11.39 and $70.40 over the past year. Currently, Wall Street analysts expect the stock to reach $77.33 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $66.81 at the most recent close of the market. An investor can expect a potential return of 15.75% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -3.66%, Pretax Profit Margin comes in at -3.89%, and Net Profit Margin reading is -4.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.95 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 65.89 points at the first support level, and at 64.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 67.32, and for the 2nd resistance point, it is at 67.83.
Ratios To Look Out For
For context, Verona Pharma Plc ADR’s Current Ratio is 10.63. As well, the Quick Ratio is 10.48, while the Cash Ratio is 9.37. Considering the valuation of this stock, the price to sales ratio is 134.62, the price to book ratio is 27.64.
Transactions by insiders
Recent insider trading involved Rickard Kathleen A., Chief Medical Officer, that happened on Mar 12 ’25 when 79264.0 shares were sold. Officer, KATHLEEN RICKARD completed a deal on Mar 12 ’25 to buy 9908.0 shares. Meanwhile, President and CEO ZACCARDELLI DAVID sold 0.64 million shares on Dec 05 ’24.
